SEC Comment Letter 0000000000-23-004849 to KIORA PHARMACEUTICALS INC (KPRX)
KIORA PHARMACEUTICALS INC
Date: May 9, 2023 · CIK: 0001372514 · Accession: 0000000000-23-004849
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-271699
Letter
United States securities and exchange commission logo May 9, 2023 Brian M. Strem, Ph.D. President and Chief Executive Officer Kiora Pharmaceuticals, Inc. 332 Encinitas Boulevard, Suite 102 Encinitas, California 92024 Re:Kiora Pharmaceuticals, Inc. Registration Statement on Form S-1 Filed May 5, 2023 File No. 333-271699 Dear Brian M. Strem: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Robert A. Petitt, Esq.
Show Raw Text
United States securities and exchange commission logo
May 9, 2023
Brian M. Strem, Ph.D.
President and Chief Executive Officer
Kiora Pharmaceuticals, Inc.
332 Encinitas Boulevard, Suite 102
Encinitas, California 92024
Re:Kiora Pharmaceuticals, Inc.
Registration Statement on Form S-1
Filed May 5, 2023
File No. 333-271699
Dear Brian M. Strem:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: Robert A. Petitt, Esq.